Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 6.2.1.59 extracted from

  • Infante, E.; Aguilar, L.D.; Gicquel, B.; Pando, R.H.
    Immunogenicity and protective efficacy of the Mycobacterium tuberculosis fadD26 mutant (2005), Clin. Exp. Immunol., 141, 21-28 .
    View publication on PubMedView publication on EuropePMC
Search for more literature for 6.2.1.59

Application

Application Comment Organism
medicine a FadD26 mutant has impaired synthesis of phthiocerol dimycocerosates and is attenuated in BALB/c mice. The FadD26 mutant induces less pneumonia and larger delayed-type hypersensitivity reactions. It induces lower but progressive production of interferon-gamma, interleukin-4 and tumour necrosis factor-alpha. Used as a subcutaneous vaccine, the mutant induces a higher level of protection than does strain Bacille Calmette-Guérin (BCG). There is less tissue damage (pneumonia) and lower colony-forming units in the mice vaccinated with the FadD26 mutant compared to the findings in mice vaccinated with BCG Mycobacterium tuberculosis

Organism

Organism UniProt Comment Textmining
Mycobacterium tuberculosis
-
-
-
Mycobacterium tuberculosis MT103
-
-
-

Synonyms

Synonyms Comment Organism
FadD26
-
 Mycobacterium tuberculosis

General Information

General Information Comment Organism
physiological function a FadD26 mutant has impaired synthesis of phthiocerol dimycocerosates and is attenuated in BALB/c mice. The FadD26 mutant induces less pneumonia and larger delayed-type hypersensitivity reactions. It induces lower but progressive production of interferon-gamma, interleukin-4 and tumour necrosis factor-alpha. Used as a subcutaneous vaccine, the mutant induces a higher level of protection than does strain Bacille Calmette-Guérin (BCG). There is less tissue damage (pneumonia) and lower colony-forming units in the mice vaccinated with the FadD26 mutant compared to the findings in mice vaccinated with BCG Mycobacterium tuberculosis